Summary by Moomoo AI
On March 20, 2024, Sera Prognostics, a health diagnostics company specializing in pregnancy care, announced its financial results for Q4 and the fiscal year ending December 31, 2023. The company reported Q4 revenue of $41,000, a decrease from $65,000 in the same period of 2022. Total operating expenses for Q4 decreased to $8.9 million from $10.5 million in the previous year. The net loss for Q4 was $7.9 million, an improvement from a $9.7 million loss in Q4 2022. For the full year, revenue increased to $306,000 from $268,000 in 2022, with total operating expenses reducing to $40.1 million from $45.9 million. The annual net loss narrowed to $36.2 million from $44.2 million. The company highlighted progress in its PRIME study for preterm birth risk assessment, product pipeline development, and commercial strategy focusing on expectant mothers. As of December 31, 2023, Sera Prognostics had approximately $79.9 million in cash, cash equivalents, and securities. The company also hosted a conference call and webcast to discuss these results and operational highlights.